| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA755: Risdiplam for treating spinal muscular atrophy in children and adults |
|
Medicine details |
|
| Medicine name | risdiplam (Evrysdi®) |
| Formulation | 0.75 mg/mL powder for oral solution |
| Reference number | 4180 |
| Indication | Treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies |
| Company | Roche Products Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/03/2021 |
| NICE guidance | TA755: Risdiplam for treating spinal muscular atrophy in children and adults |